Correction to: cGAS-STING agonists in preclinical glioblastoma animal models: a systematic review of tumor microenvironment modulation and survival outcomes - Top-Institutions - MDSpire

Correction to: cGAS-STING agonists in preclinical glioblastoma animal models: a systematic review of tumor microenvironment modulation and survival outcomes

  • By

  • Shailen G. Sampath

  • Anthony J. Tang

  • Alan X. Chen

  • Ashwin Viswanathan

  • Chiemela Izima

  • Alex H. Manriquez

  • Nicholas B. Dadario

  • Nathan Winans

  • Misha Amini

  • Nathaniel Rolfe

  • Arjun R. Adapa

  • Michael G. Argenziano

  • Colin P. Sperring

  • Justin A. Neira

  • Liang Lei

  • Peter Canoll

  • Jeffrey N. Bruce

  • June 25, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Texas M.D. Anderson Cancer Center
    University of Texas M.D. Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #4

    Harvard Medical School
    Harvard Medical School

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #5

    University of California, Los Angeles
    University of California, Los Angeles

    Los Angeles, California

    Key Differentiators

    • Oncology

Original Source(s)

Correction to: cGAS-STING agonists in preclinical glioblastoma animal models: a systematic review of tumor microenvironment modulation and survival outcomes

  • by Shailen G. Sampath, Anthony J. Tang, Alan X. Chen, Ashwin Viswanathan, Chiemela Izima, Alex H. Manriquez, Nicholas B. Dadario, Nathan Winans, Misha Amini, Nathaniel Rolfe, Arjun R. Adapa, Michael G. Argenziano, Colin P. Sperring, Justin A. Neira, Liang Lei, Peter Canoll, Jeffrey N. Bruce

  • June 25, 2026

Related Content

Metformin inhibits small intestinal neuroendocrine tumor growth in vivo

The CpG island methylator phenotype defines an immune-cold and therapy-resistant subtype of cutaneous melanoma

A New Cancer Diagnosis is Never Good—Patient Choice, Busy Health Systems, and Health Information Access :